Newron Not Seeing Sarizotan STARS Yet
FDA Calls Meeting To Discuss Rett Drug
The Italian firm has some talking to do with the US FDA before it can unblind Phase III data on sarizotan, its Rett syndrome therapy which could be "potentially transformative" for Newron.
